Objective: To probe into the efficacy of recombinant human growth hormone (rhGH) in the treatment of children with growth hormone deficiency (GHD) and its effects on the levels of thyroid function

serum insulin growth factor-1 (IGF-1) and 25-hydroxyvitamin D (25(OH)D). Methods: Seventy children with GHD admitted to our hospital from 2013 to 2017 were selected as the experimental group

and another 70 healthy children of the same age were selected as the control group. Serum levels of free triiodothyronine (FT3)

free thyroid hormone (FT4)

thyroid-stimulating hormone (TSH)

IGF-1 and 25(OH)D were detected in the experimental group before treatment and after treatment of 12 months

and compared with those in the control group. Results: After treatment of 6 and 12 months

the height

height standard deviation score

growth rate and bone age/actual age of the experimental group were significantly higher than those before treatment (P<0.05). After treatment of 12 months

the serum levels of FT3 in the experimental group increased significantly (P<0.05)

the serum levels of FT3 in the control group were higher than those in the experimental group before treatment (P<0.05). The serum levels of IGF-1 and 25(OH)D in the control group were significantly higher than those in the experimental group before and after treatment (P<0.05). Conclusion: The therapeutic effects of rhGH in the treatment of children with GHD was significant

which could significantly improve the levels of FT3 and serum IGF-1 and 25(OH)D in children.